Compare Dolby Laboratories, Inc. (DLB) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Nomura Holdings Inc — how do they compare? Dolby Laboratories, Inc. trades at $58.67 (market cap $5.47B), while Nomura Holdings Inc trades at $9.55 (market cap $27.55B). The key difference: Nomura Holdings Inc is far larger — about 5× Dolby Laboratories, Inc.'s market cap, and Nomura Holdings Inc pays the higher dividend (3.4%). Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Nomura Holdings Inc for 55 Days on average.
| DLB | NMR | |
|---|---|---|
Market Cap | $5.47B | $27.55B |
Volume | 1,058,284 | 782,470 |
Sector | Technology | Financials |
52-Week High | $70.09 | $10.86 |
52-Week Low | $48.51 | $6.73 |
Typical Hold Time | 98 Days | 55 Days |
Enterprise Value | $4.85B | $38.54T |
Dividend Yield | 2.46% | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLB trades at $58.90, up 0.94% with bearish technical signals but strong fundamentals including 87.61% gross margins and consistent earnings beats. Recent expansion with Meta and leadership transition to Marc Whitten highlight growth initiatives. Cash flow improved significantly to $215.61M in 2025 from negative trends.
Analyst consensus targets $90.33 (53% upside) with 47% buy ratings, though technical indicators signal caution. Key risks include licensing volatility and execution during leadership change. Revenue stability and premium valuation at 24.87 P/E support long-term case if growth accelerates.
Nomura Holdings (NMR) trades at $9.53, down 2.56% today amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $1.66T in 2025 and net income margin of 20.4%, but recent earnings misses and negative operating cash flow raise concerns. Valuation appears reasonable with P/E of 11.33 and P/B of 1.15. Analyst sentiment is cautious with 67% hold ratings despite recent Zacks strong buy recommendations.
The outlook remains balanced - attractive valuation and revenue growth potential are offset by cash flow challenges and technical weakness. Key risks include Japan's fiscal policy impacts on bond markets and sustained negative operating cash flow. Investors should weigh the discounted valuation against execution risks in the current macroeconomic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
